| Citation: |
ZHANG Lei, LIU Hao, JIN Ping, ZHANG Ke, WANG Xiaomei, ZHAO Yingying. Combination of SAHA and Paclitaxel Induce Apoptosis of Human Cervical Cancer HeLa Cells[J]. Cancer Research on Prevention and Treatment, 2018, 45(6): 371-375. DOI: 10.3971/j.issn.1000-8578.2018.17.0562
|
To investigate the inhibition effect of paclitaxel combined with SAHA on the proliferation of human cervical cancer HeLa cells in vitro and related mechanism.
Human cervical cancer HeLa cells were treated with paclitaxel (10 nmol/L), SAHA (10 μmol/L), and paclitaxel (10 nmol/L)+SAHA (10 μmol/L) separately for 24h or 48h. The inhibitory rate of tumor cells was determined by MTT assay. Flow cytometry was used to detect HeLa cells apoptosis and cell cycles.
MTT assay showed that the proliferation inhibitory rates of the combination group after 24h or 48h treatment were significantly higher than those of paclitaxel and SAHA groups, moreover, paclitaxel and SAHA had overlapping effects (Q=0.861, Q=1.25). SAHA combined with paclitaxel could significantly increase the apoptotic rate of HeLa cells than SAHA or paclitaxel alone. HeLa cells were randomly in G0/G1 phase after SAHA and paclitaxel treatment for 24h, which suggested that SAHA combined with paclitaxel could significantly inhibit DNA synthesis and replication during HeLa cell mitosis.
The combination of SAHA and paclitaxel could significantly induce cervical cancer HeLa cells apoptosis, inhibit cell proliferation, block cell cycle and enhance their anti-tumor ability.
| [1] |
Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy[J]. Oncogene, 2012, 31(5): 537-51. doi: 10.1038/onc.2011.267
|
| [2] |
檀琼, 刘全海.组蛋白去乙酰化酶抑制剂的研究进展[J].世界临床药物, 2010, 31(10): 616-20. http://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201414048.htm
Tan Q, Liu QH. Progress on histone deacetylase inhibitors[J]. Shi Jie Lin Chuang Yao Wu, 2010, 31(10): 616-20. http://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201414048.htm
|
| [3] |
Marks PA. Discovery and development of SAHA as an anticancer agent[J]. Oncogene, 2007, 26(9): 1351-6. doi: 10.1038/sj.onc.1210204
|
| [4] |
Hagelkruys A, Sawicka A, Rennmayr M, et al. The biology of HDAC in cancer: the nuclear and epigenetic components[J]. Handb Exp Pharmacol, 2011, 206:13-37. doi: 10.1007/978-3-642-21631-2
|
| [5] |
Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells[J]. World J Gastroenterol, 2009, 15(5): 513-20. doi: 10.3748/wjg.15.513
|
| [6] |
Hwang JJ, Kim YS, Kim MJ, et al. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells[J]. J Urol, 2010, 184(6): 2557-64. doi: 10.1016/j.juro.2010.07.035
|
| [7] |
Fitzpatrick JM, de Wit R, et al. Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer[J]. Eur Urol, 2014, 65(6): 1198-204. doi: 10.1016/j.eururo.2013.07.022
|
| [8] |
Dickinson M, Johnstone RM, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect[J]. Invest New Drugs, 2010, 28 Suppl 1: S3-20. http://www.ncbi.nlm.nih.gov/pubmed/21161327
|
| [9] |
Saelen MG, Ree AH, Kristian A, et al. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma[J]. Radiat Oncol, 2012, 7: 165. doi: 10.1186/1748-717X-7-165
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: